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WomenCervical cancer screening has reduced the incidence of cervical cancer over the past 75 years. The primary aim of
this study was to determine if women receiving Gardasil™ (HPV4 vaccine) participated in future cervical cancer
screening at the same rate as that observed for unvaccinatedwomenmatched on birth year and health care cam-
pus. This is a retrospective cohort study of subjects selected from 27,786 females born from 1980 to 1992 who
received health care in the Truman Medical Center safety net health system in Kansas City Missouri, USA. 1154
women 14–26 years old who received at least one dose of HPV4 vaccine between 2006 and 2009 were chosen
at random from the vaccine records. 1154 randomly chosen unvaccinated women were age and health campus
matched to the vaccinated women and all were followed until July 1, 2013. Women who were screened after
21 years and received three vaccine doses before 21 years, had the lowest screening rate of 24%. Their only pre-
dictive factor for screening, compared to the unvaccinated, was being closer to 21 years than 14 years at vaccina-
tion (aOR= 1.71 95% CI: 1.45, 2.00). Women vaccinated with three doses and screened at or after 21 years had
the highest screening rate of 84% predicting a six-fold increase in screening participation over no vaccine received
(aOR=5.94 95% CI: 3.77, 9.35). Our results suggest thatwomenwho receiveHPV4 vaccination closer to 21 years,
not 14, are more likely to participate in cervical cancer screening in an underserved US population.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).e Gardasil™.
ool of Medicine, USA. Fax: +1
per).
. This is an open access article underIntroduction
Much work has been published on increasing the uptake and
completion rates of HPV vaccinationwith the hopes that cervical cancer
may be prevented in the future (Cullen et al., 2014).While these efforts
are commendable, screening programs are the only proven method of
reducing cervical cancer (de Blasio et al., 2012; Harper et al., 2010;
Kulasingam et al., 2007). The longstanding effectiveness of cytologythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Control and Prevention, 2012; Committee on Practice Bulletins—
Gynecology, 2012), and most recently its effectiveness increases by
the change to include HPV testing (Moyer et al., 2012; Huh et al., 2015).
Women at the highest risk for cervical cancer are those who are
underserved and uninsured, and who seek care in the safety net health
care system (Lewin, 2000; Freeman andWingrove, 2005). The National
Cancer Institute (NCI) Center to Reduce Cancer Health Disparities
(CRCHD) postulates that cervical cancer is an indicator of larger health
system concerns, a bellwether for other health care vulnerabilities
(Freeman and Wingrove, 2005; Scarinci et al., 2010). By understanding
women's behavior in high-risk populations after HPV vaccination to-
wards future cervical cancer screening participation, we may be able
to reduce cervical cancer and its associated vulnerabilities (Freeman
and Wingrove, 2005).
A high intent to participate is noted for those adults 21 years and
older both vaccinated and unvaccinated (Alexander et al., 2014;
Anhang Price et al., 2011). On the other hand, adolescents noted a
much lower intent to screen if no vaccine or fewer than three doses
were received (Bowyer et al., 2014). The primary aim of this study
was to determine if HPV4 vaccination was a predictor of adherence to
cervical cancer screening in an underserved population. The secondary
aim is to explore whether HPV4 vaccination predicts whether women
with NILM screen results continue to participate in routine screening.Table 1
Characteristics of the study population.
Non-screen eligible Screen eligible
Age at ﬁrst or
matched vaccine dose
b21 yrs
Age at ﬁrst or
matched
vaccine dose
≥21 yrs
N = 875 N = 1433
Age at ﬁrst screening
after ﬁrst vaccine dose,
yrs, mean (SE),
range
20.6 (0.09)
14–27 yrs
25.1 (0.07)
21–35 yrs
Race/ethnicity, n (%)
White 314 (36) 500 (35)
Black 470 (54) 759 (53)
Hispanic 57 (6) 95 (6)
Other 34 (4) 78 (6)
Gravidity, n (%)
n = 0 239 (32) 196 (17)
n ≥ 1 505 (68) 972 (83)
Parity, n (%)
n = 0 272 (37) 258 (22)
n ≥ 1 472 (63) 908 (78)
Total number of doses received, n (%)
n = 0 416 (48) 738 (51)
n = 1 181 (21) 313 (22)
n = 2 118 (13) 172 (12)
n = 3 161 (18) 209 (15)
Three on-time⁎
doses completed, n (%) 110 (68) 150 (72)
SE means standard error.
Bold indicates statistical signiﬁcance at p b 0.001.
⁎ On-time dosing of HPV4was deﬁned as dose 2 is ≥4 weeks and ≤26 weeks from dose
1; dose 3 is N24 weeks and ≤52 weeks from dose 1 and dose 3 is ≥12 weeks from dose 2.Materials and methods
In this retrospective cohort study, subjects were selected from the
27,786 young women aged 14–26 years of age seen in the Truman
Medical Center (TMC) safety net health care system in Kansas City,
MO, USA between July 1, 2006 and October 1, 2009, and followed
through July 1, 2013, when the youngest vaccinated would be at
21 years of age, the US recommended screening age. TMC provides
health care at two campuses for the underinsured, uninsured or low
income patients who are at high risk for adverse health outcomes,
including cervical cancer. Study subjects were randomly chosen
among those who received at least one dose of the quadrivalent HPV
vaccine (HPV4) between July 1, 2006 and October 1, 2009 in the TMC
HPV Vaccination Program and had at least one health care visit at TMC
after vaccination and who would be of screening age as of July 1,
2013. Vaccine ascertainment was based on patient logs maintained for
vaccine accountability, billing records, and the Electronic Medical
Record (EMR).
Women who had not been vaccinated during the baseline window
or follow-up period were matched to those vaccinated by year of birth
and health care systemcampus atwhich they received health care. Like-
wise, they had at least one health care visit after the ﬁrst vaccination
date of their match and were of screening age by July 1, 2013. Age at
ﬁrst vaccine dose in this group of unvaccinated women refers to the
age at which the matched vaccinated woman received her ﬁrst HPV4
dose. Age matching was necessary to create the comparator non-
vaccinated cohort because cervical cancer screening is age dependent.
EMR data included self-identiﬁed race/ethnicity, pregnancy history,
health campus, and related screening data. TMC had no organized call/
recall program to notify patients of a need for cervical cancer screening,
something common in theUS. The cytology screeningnomenclature ad-
hered to the 2001 Bethesda system (Solomon et al., 2002)which includ-
ed negative for intraepithelial lesion or malignancy (NILM). The
observed cervical cancer screening guidelines were those in effect in
2009 (American Congress of Obstetricians and Gynecologists Commit-
tee Meeting Number 431, 2009), where the recommended age of
screening initiation was 21 years and, if NILM, screening was recom-
mended at 3-year intervals. Screening is deﬁned as too early if occur-
ring before 21 years. This study was approved by the UMKC Adult
Health Sciences Institutional Review Board (#12-351) and all requiredprotections concerning the de-identiﬁcation of data were observed
with all data de-identiﬁed prior to analysis.Statistical analysis
The age threshold used in this analysis was 21 years to correspond to
the age of initiation of cervical cancer screening (screening eligibility);
hence, both age at ﬁrst vaccination and age of ﬁrst screening thereafter
were dichotomized to younger than 21 years vs. 21 years or older.
The study was designed to have 80% power to detect an absolute
difference of 6% between screening rates among those receiving at
least one dose of HPV4 vs those with no vaccination using a Pearson's
chi-square test with a two-sided signiﬁcance level of 0.05.We calculated
that the analysis would require 1090 in each group of vaccinated and
unvaccinated women, which we increased to 1154 in each group to
allow for missing data on confounding factors abstracted from the
EMR. For all continuous variables, the mean and standard error in each
group are reported. We derived the Cochran–Armitage test for trend by
using a transformation of the linear-by-linear association provided by
SPSS (IBM Corp. (Released, 2011)).
We used conditional binary logistic regression to predict participa-
tion in cervical cancer screening by number of HPV4 vaccine doses re-
ceived (0–3) as well as demographic and obstetrical descriptors using
the unadjusted and adjusted odds ratios (ORs and aORs, respectively)
and 95% conﬁdence intervals (CIs). These analyses were performed
with Statistica version 12 (StatSoft, 2013). A two-tailed p-value of less
than 0.05 was considered statistically signiﬁcant for all analyses, except
the univariate regression,where p b 0.10was used to exclude nonsignif-
icant parameters.
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Of the 2308 women followed, 38% (875/2308) were too young for
screening participation (b21 years) at the time of ﬁrst or matched
vaccination (non-screen eligible); 62% (1433/2308) were ≥21 years.
The population descriptors in Table 1 show that the non-screen eligible
vaccinees were signiﬁcantly younger than the screen eligible vaccinees
at age of ﬁrst screening (20.6 yrs (SE 0.09) vs. 25.1 years (SE 0.07),
p b 0.001). There was no difference between the non-screen eligible
and screen eligible in distribution of doses of vaccine. Descriptors by
vaccination status are in the Supplementary Table.
Participation in cervical cancer screening varied widely by age of
ﬁrst ormatched vaccinedose. Overall, 55% (1276/2308) of the total pop-
ulation studied participated in cervical cancer screening (Table 2) with
women who received any number of vaccine doses participating in
screening signiﬁcantly more often than those without vaccination
(59% (682/1154) vs. 51% (594/1154), p b 0.001).
Among the womenwho received the ﬁrst or matched vaccine dose at
less than 21 years, a signiﬁcant proportion screened too early (b21 years)
than on time (≥21 years): 29% (258/875) vs 25% (217/875), p b 0.05. Pre-
natal screening among those less than 21 years (29% (75/258)) occurred
signiﬁcantly more often among unvaccinated women compared to vac-
cinated women (47% (54/114) vs. 15% (21/144), p b 0.001).
Among women whose ﬁrst or matched vaccine dose was ≥21
years, vaccinated women screened signiﬁcantly more often than
unvaccinated women (62% (428/694) vs. 50% (373/733), p b 0.001).
In addition, the more vaccine doses a woman received, the higher the
screening rate was (84% (175/209) vs. 62% (107/172) vs. 47% (146/
313), ptrend: three-two-one dose b 0.001)).
Screening rates amongwomen screened ≥21 yearswere signiﬁcantly
lower among women vaccinated before 21 years who received three
doses compared to three dose recipients vaccinated ≥21 years (24%
(40/161) vs. 84% (175/209), p b 0.001).
Predictors of Cervical Cancer Screening
The binary logistic regressionmodel predicted participation in cervi-
cal cancer screening using vaccination status, number of doses received,
race and pregnancy history in univariate models. A multivariate model
controlled for the signiﬁcant univariate predictors of screening to
indicate the most inﬂuential predictors (Table 3).
The model was stratiﬁed into three groups. The ﬁrst modeling
considered all women regardless of age of ﬁrst vaccine dose or age of
screening. Univariate predictors showed that womenwho had received
at least oneHPV4 dosewere signiﬁcantlymore likely than unvaccinated
women to participate in screening (OR=1.36, 95% CI: 1.16, 1.61). More
speciﬁcally, womenwho received two or three HPV4 doses were signif-
icantly more likely to participate in screening compared to women
receiving no vaccine (OR = 1.46 (95% CI: 1.12, 1.83) and OR = 2.81
(95% CI: 1.04, 1.49), respectively); whereas, women receiving a singleTable 2
Participation in Cervical Cancer Screening within 7 years of the ﬁrst HPV4 dose.
First or Matched Vaccine Dose b 21 years
N = 875
Screened b 21 years Screened ≥21 years All Screened
N = 258 N = 217 N = 475
No Vaccine, n/N (%) 114/415 (27) 107/415 (26) 221/415 (53)
Any Vaccine Doses, n/N (%) 144/460 (31) 110/460 (24) 254/460 (55)
Three Doses 62/161 (39) 40/161 (24) 102/161 (63)
Two Doses 34/118 (29) 35/118 (30) 69/118 (58)
One Dose 48/181 (27) 35/181 (19) 83/181 (46)
Bold indicates that among those receiving three doses and participating in screening at 21 years
cine dose at non-screen eligible ages was signiﬁcantly lower than the screening rate among w
Italicized indicates signiﬁcantly more women participated in screening if they were vaccinatedHPV4 dose had the same likelihood of screening participation as the
unvaccinatedwomen. Blackwomenwere 24%more likely to participate
in screening than white women (OR = 1.24, 95% CI: 1.04, 1.49).
In the multivariate model, when controlling for vaccination status,
number of doses received and race, receiving any number of doses of
HPV4 was not a signiﬁcant predictor of screening (aOR = 0.82 95% CI:
0.67, 1.02). Black women compared to white women (aOR = 1.29 95%
CI: 1.07, 1.54) and only those receiving two or three doses compared
to the unvaccinated (aOR = 1.80 95% CI: 1.34, 2.41, and aOR = 3.46
95% CI: 2.58, 4.65, respectively) were signiﬁcantly more likely to partic-
ipate in screening.
The second modeling considered those vaccinated younger than
21 years and screened ≥21 years, aswould be an appropriate population
cancer prevention plan. The closer to 21 years compared to 14 years the
woman was at vaccination, the more likely she was to participate in
screening (OR = 1.65 95% CI: 1.42, 1.92). Vaccinated compared to
unvaccinated women were signiﬁcantly more likely to participate in
screening (OR = 1.55 95% CI: 1.11, 2.16), and women receiving two or
three HPV4 doses were signiﬁcantly more likely than the unvaccinated
woman to participate in screening (OR = 2.08 95% CI: 1.30, 3.33,
OR = 1.63 95% CI: 1.05, 2.53, respectively). In addition, Black women
were 54% more likely to participate in screening than white women
(OR=1.54, 95% CI: 1.07, 2.22). In themultivariatemodel, when control-
ling for age at ﬁrst vaccination, vaccine status, number of vaccine doses
and parity, only age at ﬁrst vaccination was signiﬁcantly more likely to
predict screening participation. Speciﬁcally, we see again that the closer
to 21 years at ﬁrst vaccination compared to 14 years, the more likely the
woman participated in screening (aOR = 1.71, 95% CI: 1.45, 2.00).
The thirdmodeling consideredwomen vaccinated and screened ≥21
years. In this group, the age at ﬁrst vaccine dose was not a signiﬁcant
predictor of participation in screening.Womenwith at least one vaccine
dose were signiﬁcantly more likely to participate in screening than
unvaccinated women (OR = 1.58, 95% CI: 1.28, 1.95). Again, only
those receiving two or three doses compared to no doses were signiﬁ-
cantly more likely to participate in screening (OR = 1.61 95% CI: 1.15,
2.27 and OR= 5.05 95% CI: 3.40, 7.49, respectively). In the multivariate
model, when adjusting for vaccine status, number of doses, gravidity and
parity, vaccinated women were signiﬁcantly less likely to participate in
screening than unvaccinated (aOR = 0.48, 95% CI: 0.36, 0.65), a ﬂip
because of the disproportionate weight of single dose recipients not
participating in screening. Similarly, only those receiving two and
three doses were signiﬁcantly more likely to participate in screening
than those receiving no doses (aOR = 2.02 95% CI: 1.36, 3.01 and
aOR = 5.94 95% CI: 3.77, 9.35, respectively).
Continued routine screening
The relationship between HPV4 vaccination and adherence with
routine screening after receiving one NILM result is low. Overall,
regardless of vaccine status, only 45% (442/977) of women with NILMFirst or Matched Vaccine Dose ≥21
years
N = 1433
Total Population
N = 2308
Not Screened Screened ≥21 years Not Screened Screened Not Screened
N = 400 N = 801 N = 632 N = 1276 N = 1032
194/415 (47) 373/739 (50) 366/739 (50) 594/1154 (51) 560/1154 (49)
206/460 (45) 428/694 (62) 266/694 (38) 682/1154 (59) 472/1154 (41)
59/161 (37) 175/209 (84) 34/209 (16) 277/370 (75) 93/370 (25)
49/118 (42) 107/172 (62) 65/172 (38) 176/290 (61) 114/290 (39)
98/181 (54) 146/313 (47) 167/313 (53) 229/494 (46) 265/494 (54)
or older, the screening rate among those womenwho received their ﬁrst or matched vac-
omen who received their ﬁrst or matched vaccine dose at a screen-eligible age, p b 0.001.
than unvaccinated, pb0.001.
Table 3
Predictors of Cervical Cancer Screening Participation by Screen Eligible Age at First Vaccine Dose.
All ages regardless of age of vaccination or
screening
N = 2308
b21 years at ﬁrst vaccine and screened at
≥21 years
N = 617
≥21 years for vaccination and
screening
N = 1433
OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
Age at ﬁrst vaccination 1.02 (0.99, 1.05) 1.65 (1.42, 1.92) 1.71 (1.45, 2.00) 0.99 (0.94, 1.06)
Vaccination Status
No vaccination Referent Referent Referent Referent Referent Referent
At least one HPV4 dose 1.36 (1.16, 1.61) 0.82 (0.67, 1.02) 1.55 (1.11, 2.16) 1.00 (0.62, 1.63) 1.58 (1.28, 1.95) 0.48 (0.36, 0.65)
Number of Doses Received
n = 0 Referent Referent Referent Referent Referent Referent
n = 1 0.81 (0.66, 1.00) 1.0 1.18 (0.75, 1.85) 1.0 0.86 (0.66, 1.12) 1.0
n = 2 1.46 (1.12, 1.83) 1.80 (1.34, 2.41) 2.08 (1.30, 3.33) 1.75 (0.99, 3.08) 1.61 (1.15, 2.27) 2.02 (1.36, 3.01)
n = 3 2.81 (2.16, 3.65) 3.46 (2.58, 4.65) 1.63 (1.05, 2.53) 1.50 (0.84, 2.60) 5.05 (3.40, 7.49) 5.94 (3.77, 9.35)
Race
White Referent Referent Referent Referent Referent
Black 1.24 (1.04, 1.49) 1.29 (1.07, 1.54) 1.54 (1.07, 2.22) 1.36 (0.89, 2.08) 1.18 (0.94, 1.49)
Hispanic 0.98 (0.69, 1.39) 1.08 (0.76, 1.53) 1.20 (0.59, 2.48) 1.05 (0.49, 2.28) 0.73 (0.47, 1.13)
Other 0.97 (0.66, 1.44) 0.97 (0.65, 1.46) 1.31 (0.54, 3.16) 1.30 (0.46, 3.62) 0.99 (0.61, 1.59)
Gravidity
n = 0 Referent Referent Referent Referent
n ≥ 1 1.04 (0.83, 1.30) 1.46 (0.99,2.14) 0.57 (0.40, 0.80) 0.88 (0.46, 1.69)
Parity
n = 0 Referent Referent Referent Referent Referent
n ≥ 1 0.96 (0.78, 1.18) 1.51 (1.05, 2.81) 0.86 (0.56, 1.33) 0.59 (0.44, 0.80) 0.76(0.42, 1.34)
OR means odds ratio; aOR means adjusted OR for signiﬁcant univariate predictors. Bold font indicates statistical signiﬁcance. Odds ratios were adjusted for signiﬁcant univariate
parameters within each age group. 95% CI means 95% conﬁdence interval.
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There was signiﬁcantly greater adherence to participating in a second
screening among those who received three HPV4 doses compared to
the unvaccinated woman (62% (127/205) vs. 40% (193/477), p b 0.001).
Moreover, only 52% (105/201) of early NILM result screeners (b21
years) returned for a second screen during the 6.5 year study follow-up,
and only half were older than 21 years at this second routine screen.
Nonetheless, screening participation among women receiving three
doses was signiﬁcantly decreased at the second round compared to the
rate of initial screening (62% (127/205) vs 75% (277/470), p b 0.01).
Stratifying by age of ﬁrst HPV4 vaccination, those younger than
21 years at ﬁrst HPV4 dose had signiﬁcantly lower routine second
screen rates than those women whose ﬁrst vaccine dose was at or
older than 21 years (13% (11/78) vs 64% (81/147), p b 0.05).
Predictors of continued screening after an initial NILM result are
presented in Table 5. Among all women, while vaccine status predicted
signiﬁcantly lower chances of routine screening than unvaccinated
women after an initial NILM result (OR = 0.68 (95% CI: 0.53, 0.88)),
women receiving three doses of HPV4 were signiﬁcantly more likely
to adhere to routine screening than the unvaccinated woman (OR =
2.40 (95% CI: 1.71, 3.35)). The multivariate logistic regression resulted
in older age and receiving three doses of HPV4 being the only predictorsTable 4
Subsequent Routine Cervical Cancer Screening amongWomen with an initial Negative for Intr
Second Routine Screen
First or Matched Vaccine Dose b 21 years
N = 365
1st and 2nd Screen b 21 yrs 1st and 2nd Screen ≥21 yrs All 2nd
N = 48 N = 39 N = 14
No Vaccine, n/N (%) 18/172 (10) 17/172 (10) 59/172
AnyVaccinedoses, n/N (%) 30/193 (16) 22/193 (11) 85/193
Three Doses 12/78 (15) 11/78 (13) 46/78 (
Two Doses 10/54 (19) 5/54 (9) 19/54 (
One Dose 8/61 (13) 6/61 (10) 20/61 (
Bold indicates statistically signiﬁcant differences in appropriate aged screening for three doses
whose ﬁrst screening was NILM were signiﬁcantly more likely to participate in a second screenfor adherence to follow up routine screening (aOR= 1.08 (95% CI: 1.03,
1.13) and 2.34 (1.51, 3.61) respectively).
Among the young vaccinees screening ≥21 years, there were two
strong predictors for routine screening adherence. The closer the age
of vaccination was to 21 years from 14 years, the greater the likelihood
of adherence to future screening (OR = 1.83 (95% CI: 1.16, 2.88)).
Similarly, receiving three doses compared to nonewas a signiﬁcant pre-
dictor of adherence to routine screening (OR = 2.72 (1.06, 6.99)). In
multivariate modeling, both age of vaccination and receiving three
HPV4 doses retained their signiﬁcance, indicating those who received
vaccine closer to 21 years and who received all three doses compared
to none, were signiﬁcantly more likely to adhere to continued routine
screening (aOR = 2.06 (95% CI: 1.28, 3.32) and aOR = 3.46 (95% CI:
1.25, 9.59), respectively).
Finally, among women vaccinated and screened ≥21 years, women
were signiﬁcantly more likely to adhere to routine screening if they
had at least one vaccine dose compared to none (OR = 1.46 (95% CI:
1.06, 2.01)), but speciﬁcally had received all three doses of vaccine
(OR = 2.25 (95% CI: 1.47, 3.44)) compared to none. In the multivariate
model, when controlling for these variables, womenwho received three
HPV4 doses were signiﬁcantly more likely than the unvaccinated
women to adhere to routine screening (aOR = 1.84 (1.17, 2.89)).aepithelial Lesions or Malignancy (NILM) Result.
First or Matched Vaccine
Dose ≥21 years
N = 612
Total Population
N = 977
Screens No 2nd Screen 2nd Screen No 2nd Screen 2nd Screen No 2nd Screen
4 N = 221 N = 298 N = 314 N = 442 N = 535
(34) 113/172 (66) 134/305 (44) 171/305 (56) 193/477 (40) 284/477 (60)
(44) 108/193 (56) 156/299 (52) 143/299 (48) 249/500 (50) 251/500 (50)
59) 32/78 (41) 81/127 (64) 46/127 (36) 127/205 (62) 78/205 (38)
35) 35/54 (65) 40/79 (51) 39/79 (49) 59/133 (44) 74/133 (56)
33) 41/61 (67) 43/101 (43) 58/101 (57) 63/162 (39) 99/162 (61)
of vaccine received, p b 0.001. Italicized indicates that women receiving three doses and
than the unvaccinated, pb0.001.
Table 5
Predictors of Second Cervical Cancer Screening Participation after ﬁrst NILM result.
All ages regardless of age of vaccination
or ﬁrst screening
N = 977
b21 years at ﬁrst vaccine and ﬁrst
screened at ≥21 years
N = 164
≥21 years for vaccination and screening
N = 612
OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
Age at ﬁrst vaccination 1.05 (1.00, 1.10) 1.08 (1.03, 1.13) 1.83 (1.16, 2.88) 2.06 (1.28, 3.32) 1.01 (0.92, 1.11)
Vaccination Status
No vaccination Referent Referent Referent Referent Referent
At least one HPV4 dose 0.68 (0.53, 0.88) 0.91 (0.62, 1.32) 1.31 (0.64, 2.71) 1.46 (1.06, 2.01) 1.0
Number of Doses Received
n = 0 Referent Referent Referent Referent Referent Referent
n = 1 0.94 (0.65, 1.35) 1.0 0.93 (0.33, 2.63) 0.80 (0.27, 2.32) 0.95 (0.60, 1.49) 0.88 (0.55, 1.41)
n = 2 1.17 (0.80, 1.73) 1.21 (0.75, 1.95) 0.81 (0.27, 2.43) 0.67 (0.22, 2.10) 1.31 (0.80, 2.15) 1.15 (0.68, 1.94)
n = 3 2.40 (1.71, 3.35) 2.34 (1.51, 3.61) 2.72 (1.06, 6.99) 3.46 (1.25, 9.59) 2.25 (1.47, 3.44) 1.84 (1.17, 2.89)
Race
White Referent Referent Referent
Black 1.13 (0.86, 1.49) 1.15 (0.51, 2.58) 1.22 (0.87, 1.73)
Hispanic 0.61 (0.35, 1.07) 0.33 (0.04, 2.85) 0.90 (0.38, 1.65)
Other 0.53 (0.27, 1.04) 0.65 (0.07, 6.21) 0.64 (0.30, 1.38)
Gravidity
n = 0 Referent Referent Referent Referent Referent
n ≥ 1 0.61 (0.45, 0.83) 0.78 (0.40, 1.50) 1.13 (0.47, 2.74) 0.52 (0.34, 0.80) 0.41 (0.18, 0.96)
Parity
n = 0 Referent Referent Referent Referent Referent
n ≥ 1 0.63 (0.47, 0.85) 0.78 (0.43, 1.44) 0.90 (0.39, 2.12) 0.66 (0.45, 0.97) 1.42 (0.67, 3.02)
OR means odds ratio; aOR means adjusted OR for signiﬁcant univariate predictors. Bold indicates statistical signiﬁcance. Odds ratios were adjusted for signiﬁcant univariate parameters
within each age group. 95% CI means 95% conﬁdence interval
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We report that participation in cervical cancer screening among the
women choosing no HPV vaccination in this underserved, high-risk
population is signiﬁcantly lower (50%) than would be anticipated
from US Behavioral Risk Factor Surveillance System (BRFSS) responses,
which in 2012 were 86% for women 21–29 years old (Benard et al.,
2007), and 81% from the US National Health Interview Survey (NHIS)
study (Bowyer et al., 2014). An Australian report of women choosing
no HPV vaccination during an active HPV vaccine program also showed
that unvaccinated adult women screened at similarly low rates: 20–24
year olds at 48% and 25–29 year olds at 59%, despite an organized noti-
ﬁcation system for screening (Budd et al., 2014). While our population
historically has had the poorest screening rates in the US, with the
advent of HPV vaccines, we have not seen a decrease in the baseline
rate, whereas both the UK and the Scottish NHS reported much lower
screening rates among their unvaccinated women at 39% and 30%
during active HPV vaccination programs compared to prior to the vac-
cine programs (Beer et al., 2014 Apr 1; Pollock et al., 2014).These low
screening rates are concerning not only because these women are the
ones choosing noHPV vaccination, but becausemost cervical cancer oc-
curs in those with no screening or screening at prolonged intervals
which is signiﬁcantly more common among high-risk women (Drolet
et al., 2013). Including the unknown duration of HPV vaccine efﬁcacy,
and that none of the HPV vaccines prevents all cervical cancers, the
need for promoting screening participation during HPV vaccination
programs is essential.
Vaccinated women in our high risk population participated in
screening more often than the unvaccinated, and in a manner
dependent on the number of HPV4 vaccine doses received. Women
receiving three doses ≥21 years had the best screening rate of 84%, equiv-
alent to the Healthy People 2020 baseline screening rate (Healthy People,
2020). It is plausible that the three visits for vaccination ≥21 years provide
an increased opportunity to discuss and participate in screening, as we
saw signiﬁcantly lower screening rates among those receiving only one
(47%) or two (62%) doses. In addition, vaccinated women were more
often screened than unvaccinated women in a Danish and two US survey
studies (Sauer et al., 2015; Beer et al., 2014 Apr 1; Baldur-Felskov et al.,
2014 Mar), whereas the Australian study showed lower screening rates
among the vaccinated (Budd et al., 2014).Nevertheless, the population targeted for vaccination and screening
is that whose vaccinations are separated bymany years from screening.
In our study, participation rates in screening among the women vacci-
nated younger than 21 years and screened ≥21 years dropped to an
unacceptably low rate of 24%, not different from the unacceptably low
26% screening rate of unvaccinated women in this same cohort. It is
important to call out that the only predictor of screening participation
in this targeted age group of women was an age closer to 21 than 14
years. This is particularly important to note as we have shown
that three dose HPV vaccination at screen eligible ages (≥21 years)
predicts nearly a six-fold increase in screening compared to the
unvaccinated in our high-risk population.
We also document inappropriate screening in that 54% (258/475) of
screened women, vaccinated younger than 21 years, were screened
inappropriately before 21 years. While some would posit that any
screening after vaccination is a successful outcome, we believe that for
those young adolescents to whom HPV vaccination is targeted, a 29%
(258/875) screen rate before reaching 21 years wastes resources for
no measurable health outcome. Participating in screening too early is
harmful: cytology is not sensitive for CIN 3 detection at young ages,
the examination and screening is costly, and the speculum examination
creates unproductive anxiety in the young woman (Committee on
Practice Bulletins—Gynecology, 2012; Reddy and Wasserman, 1997;
Snodgrass and Naugler, 2014).
Moreover, a NILM result may inappropriately reassure a young
woman that she does not have cancer and dissuade her from future
screening (Henderson et al., 2011). Failure-to-screen behavior is a pre-
dictor of cervical cancer; Leyden et al (Leyden et al., 2005) showed
that 31% of the cervical cancers diagnosed in women 16–39 years old
were associated with no screen in the prior 3 years. Our data show
that there is a high risk of failure to continue screening in the presence
of a NILM result after early vaccination. In fact, the only predictors of
participation in routine screening after an initial NILM result for the
targeted young vaccinee who waited until 21 years or older for screen-
ingwas an age of vaccine closer to 21 years than 14 years, and receiving
three vaccine doses compared to no doses.
The limitations of our study include the fact that it is a retrospective
cohort studywhere screening call/recall is not used in an organized pro-
gram. All age-appropriate women presenting to our safety net health
care system were offered HPV vaccination during the time frame of
716 C.A. Paynter et al. / Preventive Medicine Reports 2 (2015) 711–716the study, eliminating unequal access to the vaccine as a source of bias.
Likewise, all women reached the screening age of 21 years by study end
and had had at least one other health care visit for health care concerns
by study end, minimizing the possibility that the women chose to be
screened outside of this health care system, which is a possibility, al-
though unlikely.
Information biases may be present, as well, in both screening and
vaccination ascertainment. The EMR may include unknown recording
errors that may have produced misclassiﬁcation of screening status. In
addition, while the vaccination logs for all administration of HPV4
vaccines may exclude doses given but not recorded, the pharmacy log
of doses given completely agrees with the vaccination log making it
highly unlikely that vaccine doses were misclassiﬁed in this catchment
population. Our study is observational and therefore identiﬁes only
statistical associations which may or may not reﬂect causal relation-
ships. A strength of our study, however, is the relatively large sample
size in a captured safety net population.
Conclusions
In summary,we strongly recommend continuing active HPV vaccina-
tion programs among women ≥21 years at the same time as screening.
Because our results show that adolescent HPV vaccination efforts
have not resulted in adequate screening participation, we recommend
vigorous counseling for screening at the time of vaccination.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.pmedr.2015.07.011.
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